valomaciclovir stearate
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00575185)
Timeline
Indications
Mechanism of action
- Human herpesvirus 4INHIBITOR
Human herpesvirus 4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CCOC(=O)[C@@H](N)C(C)C)Cn1cnc2c(=O)[nH]c(N)nc21- Mol. weight
- 618.86 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107301 ↗
- ChEMBLCHEMBL2105845 ↗
Also known as
- ((3r)-3-((2-amino-6-oxo-3h-purin-9-yl)methyl)-4-hydroxy-butyl) (2s)-2-amino-3-methyl-butanoate
- a-174606.0
- a-174606.0
- abt-606
- abt-606
- epb-348
- epb-348
- miv606
- miv-606
- miv-606
- miv-606
- valomaciclovir
- valomaciclovir
- valomaciclovir
- valomaciclovir
- valomaciclovir stearate
- valomaciclovir stearate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00575185 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2007 | Epiphany Biosciences, University of Minnesota |
| NCT00831103 | Phase 2 | Nov 1, 2007 | Epiphany Biosciences, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epiphany Biosciences | For profit | 2 | 1 | 1 | 2007 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2007 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1